NCT01560052 (TESTING) is a NA clinical trial of methylprednisolone in IgA Glomerulonephritis, sponsored by The George Institute.

Who is sponsoring NCT01560052?

NCT01560052 is sponsored by The George Institute.

What drugs are being tested in NCT01560052?

Interventions in NCT01560052: methylprednisolone, Placebo.

What condition does NCT01560052 study?

NCT01560052 studies IgA Glomerulonephritis.

Is NCT01560052 still recruiting?

NCT01560052 is currently completed. Last updated 23 September 2021.

Last reviewed 2021-09-23 · How we verify

NCT01560052: TESTING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)

Completed NA Last updated 23 September 2021

What this trial tests

NA trial testing methylprednisolone in IgA Glomerulonephritis in 503 participants. Completed in 23 July 2021.

Timeline

5 May 2012

Primary endpoint
23 July 2021

23 July 2021

Quick facts

Lead sponsor	The George Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	503
Start date	5 May 2012
Primary completion	23 July 2021
Estimated completion	23 July 2021
Sites	66 locations across Hong Kong, Malaysia, Canada, Australia, China, India

Drugs / interventions tested

methylprednisolone (methylprednisolone) — full drug profile →
Placebo

Conditions studied

IgA Glomerulonephritis — all drugs for IgA Glomerulonephritis →

Sponsor

The George Institute

Who can join

18 and older, any sex, with IgA Glomerulonephritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the long-term efficacy and safety of low dose oral methylprednisolone compared to matching placebo, on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

IgA Nephropathy.
Rodrigues JC, Haas M, Reich HN. · · 2017 · cited 407× · PMID 28159829 · DOI 10.2215/cjn.07420716
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J, Zhang H, Wong MG, Jardine MJ, et al · · 2017 · cited 402× · PMID 28763548 · DOI 10.1001/jama.2017.9362
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J, Wong MG, Hladunewich MA, Jha V, et al · · 2022 · cited 245× · PMID 35579642 · DOI 10.1001/jama.2022.5368
Current treatment of IgA nephropathy.
Floege J, Rauen T, Tang SCW. · · 2021 · cited 104× · PMID 34495361 · DOI 10.1007/s00281-021-00888-3
Immunosuppressive agents for treating IgA nephropathy.
Natale P, Palmer SC, Ruospo M, Saglimbene VM, et al · · 2020 · cited 61× · PMID 32162319 · DOI 10.1002/14651858.cd003965.pub3
New strategies and perspectives on managing IgA nephropathy.
Selvaskandan H, Cheung CK, Muto M, Barratt J. · · 2019 · cited 61× · PMID 30756248 · DOI 10.1007/s10157-019-01700-1
An Update on the Current State of Management and Clinical Trials for IgA Nephropathy.
Cheung CK, Rajasekaran A, Barratt J, Rizk DV. · · 2021 · cited 41× · PMID 34200024 · DOI 10.3390/jcm10112493
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Wong MG, Lv J, Hladunewich MA, Jha V, et al · · 2021 · cited 25× · PMID 34731857 · DOI 10.1159/000519812

Verify or expand the search:

Other trials of methylprednisolone

Trials testing the same drug.

NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
NCT06623370 — The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group · Phase 4 · completed
NCT04826237 — Oral Statins and Protection From Hearing Loss · Phase 4 · recruiting
NCT05137496 — Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome · Phase 3 · unknown

Other The George Institute trials

Trials by the same sponsor.

NCT07231315 — INTERACT4 Expansion - Validation Study · not yet recruiting
NCT04157231 — Essential Acute Stroke Care in Low Resource Settings: a Pilot studY · NA · not yet recruiting
NCT06935760 — Optimised Treatment for Hypertension Trial · NA · not yet recruiting
NCT06409364 — FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage · Phase 2 · recruiting
NCT06058585 — The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01560052 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The George Institute
Last refreshed: 23 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01560052.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing